Working... Menu

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01942486
Recruitment Status : Unknown
Verified May 2017 by Bradley Katz, University of Utah.
Recruitment status was:  Recruiting
First Posted : September 16, 2013
Last Update Posted : May 3, 2017
Primary Children's Hospital
Information provided by (Responsible Party):
Bradley Katz, University of Utah

Brief Summary:
The purpose of this study is to determine if a special coating, applied to the surface of glasses can reduce the frequency and severity of migraine headaches in children and adolescents. This study is being conducted by researchers at Primary Children's Medical Center, The John Moran Eye Center, and the University of Utah Department of Electrical Engineering. The investigators have determined that a specific frequency of light is particularly bothersome to migraine patients. The coating they've developed is designed to block this frequency of light. Very few treatments are approved for the treatment of childhood migraine. The investigators hope that these glasses will provide a safe way to improve headaches in children.

Condition or disease Intervention/treatment Phase
Migraine Disorders Photophobia Device: Investigational Coating Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine
Study Start Date : January 2014
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Investigational Coating Device: Investigational Coating

Primary Outcome Measures :
  1. HIT-6 Score [ Time Frame: 12 weeks ]
    The HIT-6 (Headache Impact Test) is a validated measure of the impact of headache on activities of daily living, functional health and well-being.

Secondary Outcome Measures :
  1. Headache Frequency as Measured Using a Self-Reporting Daily Diary [ Time Frame: 12 weeks ]
    Headache frequency will be assessed using daily headache diary entries provided by subjects

Other Outcome Measures:
  1. Headache Severity as Measured Using a Visual Analog Scale and a Self-Reported Daily Diary [ Time Frame: 12 weeks ]
    Subjects will rate the severity of their headaches throughout the study using a visual analog scale as part of a daily headache diary.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be diagnosed with migraine with aura or migraine without aura
  2. Must have at least 10 headache days per month

Exclusion Criteria:

  1. Currently wearing a spectacle tint specifically prescribed for migraine or light sensitivity
  2. Pregnant
  3. Unwilling or unable in the judgment of the investigator to complete the study
  4. Unavailable for any of the study visits
  5. Light sensitive conditions: meningitis, iritis, blepharospasm, albinism
  6. Degenerative diseases of the retina or optic nerve: diabetic retinopathy, ischemic optic neuropathy
  7. Medications known to affect retinal or optic nerve function: hydroxychloroquine, chloroquine, ethambutol, amiodarone, erectile dysfunction drugs
  8. Best corrected visual acuity less than 20/40 in either eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01942486

Layout table for location contacts
Contact: Katie Rogers 801-585-6647

Layout table for location information
United States, Utah
Moran Eye Center Recruiting
Salt Lake City, Utah, United States, 84132
Principal Investigator: Bradley Katz, MD         
Sponsors and Collaborators
University of Utah
Primary Children's Hospital
Layout table for investigator information
Principal Investigator: Bradley Katz, MD University of Utah

Layout table for additonal information
Responsible Party: Bradley Katz, M.D., University of Utah Identifier: NCT01942486     History of Changes
Other Study ID Numbers: IRB_00065178
First Posted: September 16, 2013    Key Record Dates
Last Update Posted: May 3, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Bradley Katz, University of Utah:
light sensitivity
melanopsin cells
intrinsically photosensitive retinal ganglion cells

Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Immune System Diseases
Neurologic Manifestations
Signs and Symptoms
Vision Disorders
Sensation Disorders
Eye Diseases